HTG Molecular Diagnostics Expands Distribution into Israel, Spain and Portugal

HTG Molecular Diagnostics Announces Distribution Agreements with Gamidor in Israel and Durviz in Spain and Portugal

HTG Logo Spot-sized copy

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.

“By expanding our distribution reach into these markets, we believe the availability of the HTG EdgeSeq system and assays will accelerate the adoption of molecular profiling using NGS,” stated Jean Claude Gerard, PhD, VP European Commercial Operations for HTG Molecular Diagnostics.  Dr. Gerard added, “Both Gamidor and Durviz are as passionate as we are at HTG about enabling precision medicine at the local level.”

Gamidor provides systems, chemicals, reagents and services in Israel, offering state-of-the-art diagnostic solutions to hospitals, health management systems and academic research institutes.  Durviz is a distributor of next-generation sequencing reagents and library preparation systems in Spain and Portugal.

“These agreements serve to expand HTG’s reach outside the United States and we see our agreements with Gamidor and Durviz as models for additional agreements with distributors in select global markets,” stated TJ Johnson, President and CEO of HTG Molecular Diagnostics.

About HTG:

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing.

Additional information and Notice of Forward Looking Statements are available at

Posted in AZBio News.